Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2004)
Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction
Bethan Hughes (2010)
2009 FDA drug approvalsNature Reviews Drug Discovery, 9
J. Mcconnell (2006)
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Polina Plotkin, Khusbu Patel, A. Uminski, N. Marzella (2011)
Telavancin (vibativ), a new option for the treatment of gram-positive infections.P & T : a peer-reviewed journal for formulary management, 36 3
A. Rivera, H. Boucher (2011)
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.Mayo Clinic proceedings, 86 12
D. Higgins, R. Chang, D. Debabov, J. Leung, Terry Wu, K. Krause, E. Sandvik, J. Hubbard, K. Kaniga, D. Schmidt, Qiufeng Gao, R. Cass, D. Karr, Bret Benton, P. Humphrey (2005)
Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 49
E. Goldstein, D. Citron, C. Merriam, Y. Warren, K. Tyrrell, H. Fernandez (2003)
In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical IsolatesAntimicrobial Agents and Chemotherapy, 47
A. King, I. Phillips (2001)
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.The Journal of antimicrobial chemotherapy, 48 2
N. Holmes, S. Tong, Joshua Davis, S. Hal (2015)
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and BeyondSeminars in Respiratory and Critical Care Medicine, 36
J. Swenson, P. Williams, G. Killgore, C. O'hara, F. Tenover (2001)
Performance of Eight Methods, Including Two New Rapid Methods, for Detection of Oxacillin Resistance in a Challenge Set ofStaphylococcus aureus OrganismsJournal of Clinical Microbiology, 39
Melinda Lacy, M. Stryjewski, Whedy Wang, Thomas Hardin, Boris Nogid, David Luke, Andrew Shorr, G. Corey, Steven Barriere (2015)
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 Suppl 2
Junlan Chuan, Yuan Zhang, Xia He, Yuxuan Zhu, Lei Zhong, Dongke Yu, Hongtao Xiao (2016)
Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Frontiers in Pharmacology, 7
M. Rybak, E. Hershberger, Tabitha Moldovan, Richard Grucz (2000)
In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant StrainsAntimicrobial Agents and Chemotherapy, 44
A. King, I. Phillips, K. Kaniga (2004)
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.The Journal of antimicrobial chemotherapy, 53 5
Li-Yan Yin, J. Calhoun, Theodore Thomas, Eric Wirtz (2008)
Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.The Journal of antimicrobial chemotherapy, 63 2
D. Amanatullah, Matthew Lopez, R. Gosselin, Munish Gupta (2013)
Case Report: Artificial Elevation of Prothrombin Time by TelavancinClinical Orthopaedics and Related Research®, 471
D. Talan, A. Krishnadasan, R. Gorwitz, G. Fosheim, B. Limbago, V. Albrecht, G. Moran (2011)
Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 53 2
K. Polyzos, M. Mavros, K. Vardakas, M. Makris, P. Rafailidis, M. Falagas (2012)
Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-AnalysisPLoS ONE, 7
S. Hegde, Stacey Difuntorum, R. Skinner, J. Trumbull, K. Krause (2009)
Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.The Journal of antimicrobial chemotherapy, 63 4
D. Robinson, M. Enright (2003)
Evolutionary Models of the Emergence of Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 47
K. Krause, M. Renelli, Stacey Difuntorum, Terry Wu, D. Debabov, Bret Benton (2008)
In Vitro Activity of Telavancin against Resistant Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 52
U. Theuretzbacher (2011)
Resistance drives antibacterial drug development.Current opinion in pharmacology, 11 5
S. Wilson, W. O'Riordan, A. Hopkins, H. Friedland, S. Barriere, M. Kitt (2009)
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.American journal of surgery, 197 6
K. Laupland, D. Church, Melissa Mucenski, L. Sutherland, H. Davies (2003)
Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections.The Journal of infectious diseases, 187 9
J. Frère, S. Rigali (2016)
The alarming increase in antibiotic-resistant bacteria
(2014)
Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureusClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 60
W. Abdelhady, A. Bayer, R. Gonzales, Liang Li, Y. Xiong (2016)
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus StrainsAntimicrobial Agents and Chemotherapy, 61
G. Candiani, M. Abbondi, M. Borgonovi, G. Romanó, F. Parenti (1999)
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.The Journal of antimicrobial chemotherapy, 44 2
A. Pakyz, C. MacDougall, M. Oinonen, R. Polk (2008)
Trends in antibacterial use in US academic health centers: 2002 to 2006.Archives of internal medicine, 168 20
M. Bassetti, M. Merelli, C. Temperoni, A. Aştilean (2013)
New antibiotics for bad bugs: where are we?Annals of Clinical Microbiology and Antimicrobials, 12
G. Zhanel, D. Calic, F. Schweizer, S. Zelenitsky, H. Adam, P. Lagacé-Wiens, E. Rubinstein, A. Gin, D. Hoban, J. Karlowsky (2010)
New LipoglycopeptidesDrugs, 70
M. Zeckel, D. Preston, B. Allen (2000)
In Vitro Activities of LY333328 and Comparative Agents against Nosocomial Gram-Positive Pathogens Collected in a 1997 Global Surveillance StudyAntimicrobial Agents and Chemotherapy, 44
Heather Sun, K. Duchin, C. Nightingale, J. Shaw, J. Seroogy, D. Nicolau (2006)
Tissue Penetration of Telavancin after Intravenous Administration in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 50
A. Madrigal, Li Basuino, H. Chambers (2005)
Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 49
E. Sillerström, E. Wahlund, C. Nord (1999)
In vitro activity of LY 333328 against anaerobic gram-positive bacteria.Journal of chemotherapy, 11 2
Alison Larsson, K. Walker, J. Raddatz, J. Rotschafer (1996)
The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions.The Journal of antimicrobial chemotherapy, 38 4
S. Finegold, M. Bolaños, Paula Sumannen, D. Molitoris (2009)
In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 53
F. García-Garrote, E. Cercenado, L. Alcalá, E. Bouza (1998)
In Vitro Activity of the New Glycopeptide LY333328 against Multiply Resistant Gram-Positive Clinical IsolatesAntimicrobial Agents and Chemotherapy, 42
E. Goldstein, D. Citron, C. Merriam, Y. Warren, K. Tyrrell, H. Fernandez (2004)
In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium sppAntimicrobial Agents and Chemotherapy, 48
Noe Reyes, R. Skinner, Bret Benton, K. Krause, Josephine Shelton, G. Obedencio, S. Hegde (2006)
Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.The Journal of antimicrobial chemotherapy, 58 2
C. Ford, J. Hamel, Debbie Wilson, J. Moerman, D. Stapert, R. Yancey, D. Hutchinson, M. Barbachyn, S. Brickner (1996)
In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infectionsAntimicrobial Agents and Chemotherapy, 40
(2014)
VIBATIV (Procedure No
R. Jones, D. Biedenbach, David Johnson, M. Pfaller (2001)
In Vitro Evaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 13
H. Grundmann, M. Aires-de-Sousa, J. Boyce, E. Tiemersma (2006)
Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threatThe Lancet, 368
S. Wong, F. Sörgel, M. Kinzig, M. Goldberg, M. Kitt, S. Barriere (2009)
Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy ParticipantsThe Journal of Clinical Pharmacology, 49
J. Lentino, M. Narita, V. Yu (2007)
New antimicrobial agents as therapy for resistant gram-positive cocciEuropean Journal of Clinical Microbiology & Infectious Diseases, 27
C. Lunde, Stephanie Hartouni, J. Janc, M. Mammen, P. Humphrey, Bret Benton (2009)
Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid IIAntimicrobial Agents and Chemotherapy, 53
Bret Benton, E. Breukink, I. Visscher, D. Debabov, C. Lunde, J. Janc, M. Mammen, P. Humphrey (2007)
O258 Telavancin inhibits peptidoglycan biosynthesis through preferential targeting of transglycosylation: evidence for a multivalent interaction between telavancin and lipid IIInternational Journal of Antimicrobial Agents, 29
Comparative activities of dalbavancin ( DAL ) against staphylococci , including a vancomycin resistant strain of Staphylococcus aureus
P. Courvalin (2006)
Vancomycin resistance in gram-positive cocci.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 Suppl 1
(2006)
TelavancinDrugs in R & D, 7
S. Barriere, F. Genter, E. Spencer, M. Kitt, D. Hoelscher, J. Morganroth (2004)
Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy SubjectsThe Journal of Clinical Pharmacology, 44
M. Rashid, A. Weintraub, C. Nord (2011)
Effect of telavancin on human intestinal microflora.International journal of antimicrobial agents, 38 6
T. Nanovskaya, S. Patrikeeva, Ying Zhan, V. Fokina, G. Hankins, Mahmoud Ahmed (2012)
Transplacental transfer of vancomycin and telavancin.American journal of obstetrics and gynecology, 207 4
M. Gotfried, J. Shaw, Bret Benton, K. Krause, M. Goldberg, M. Kitt, S. Barriere (2007)
Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other AntibioticsAntimicrobial Agents and Chemotherapy, 52
J. Streit, T. Fritsche, H. Sader, Ronald Jones (2004)
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.Diagnostic microbiology and infectious disease, 48 2
E. Rubinstein, G. Corey, M. Stryjewski, Z. Kanafani (2011)
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumoniaExpert Opinion on Pharmacotherapy, 12
R. Fass, V. Helsel (1986)
In vitro activity of LY146032 against staphylococci, streptococci, and enterococciAntimicrobial Agents and Chemotherapy, 30
E. Rubinstein, T. Lalani, G. Corey, Z. Kanafani, E. Nannini, Marcelo Rocha, G. Rahav, M. Niederman, M. Niederman, M. Kollef, A. Shorr, P. Lee, A. Lentnek, C. Luna, J. Fagon, A. Torres, M. Kitt, F. Genter, S. Barriere, H. Friedland, M. Stryjewski (2011)
Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive PathogensClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 52
Richard Pushkin, S. Barriere, Whedy Wang, G. Corey, M. Stryjewski (2015)
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA GuidanceAntimicrobial Agents and Chemotherapy, 59
R. Jones, D. Johnson, M. Erwin (1996)
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinonesAntimicrobial Agents and Chemotherapy, 40
S. Schmidt, Melissa Karau, J. Mandrekar, J. Steckelberg, Robin Patel (2012)
Telavancin in Experimental Murine Pneumococcal Pneumonia, 1
E. Goldstein, D. Citron, Y. Warren, K. Tyrrell, C. Merriam, H. Fernandez (2006)
In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot InfectionsAntimicrobial Agents and Chemotherapy, 50
A. Stucki, P. Gerber, F. Acosta, M. Cottagnoud, P. Cottagnoud (2006)
Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic ParametersAntimicrobial Agents and Chemotherapy, 50
C. Lunde, C. Rexer, Stephanie Hartouni, S. Axt, Bret Benton (2010)
Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 54
S. Lopez, C. Hackbarth, G. Romanó, J. Trias, D. Jabes, B. Goldstein (2005)
In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.The Journal of antimicrobial chemotherapy, 55 Suppl 2
M. Rybak, D. Cappelletty, Tabitha Moldovan, J. Aeschlimann, G. Kaatz (1998)
Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 42
V. Salvi, D. Karnad, Gopi Panicker, S. Kothari (2010)
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentBritish Journal of Pharmacology, 159
J. Streit, H. Sader, T. Fritsche, Ronald Jones (2005)
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.Diagnostic microbiology and infectious disease, 53 4
Gengrong Lin, Kim Credito, L. Ednie, P. Appelbaum (2005)
Antistaphylococcal Activity of Dalbavancin, an Experimental GlycopeptideAntimicrobial Agents and Chemotherapy, 49
R. Masterton, G. Cornaglia, P. Courvalin, H. Lode, J. Rello, A. Torres (2015)
The clinical positioning of telavancin in Europe.International journal of antimicrobial agents, 45 3
Deborah Draghi, Bret Benton, K. Krause, C. Thornsberry, C. Pillar, D. Sahm (2008)
Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 52
S. Hegde, Noe Reyes, T. Wiens, Nicole Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J. Shaw, G. Obedencio, J. Judice (2004)
Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 48
I. Odenholt, E. Löwdin, O. Cars (2007)
Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic ModelAntimicrobial Agents and Chemotherapy, 51
S. Gander, A. Kinnaird, R. Finch (2005)
Telavancin: in vitro activity against staphylococci in a biofilm model.The Journal of antimicrobial chemotherapy, 56 2
Y. Xiong, Wessam Hady, A. Bayer, Liang Chen, B. Kreiswirth, Soo-Jin Yang (2012)
Telavancin in Therapy of Experimental Aortic Valve Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 56
Solomon, Horan, Andrus, Edwards (2002)
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002.American journal of infection control, 30 8
M. Stryjewski, Donald R. Graham, Samuel E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. Ross, V. Fowler, A. Hopkins, H. Friedland, Steven Barriere, M. Kitt, G. Corey (2008)
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46 11
T. Lodise, J. Butterfield, S. Hegde, E. Samara, Steven Barriere (2012)
Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal FunctionAntimicrobial Agents and Chemotherapy, 56
M. Fisher, G. Overturf, M. Capello, M. Cappello, E. Chadwick, J. Englund, L. Krilov, C. Leach, K. Mcgann, J. Starke, G. Weinberg, L. Weiner, C. Woods (2010)
Management of Infections Caused by Vancomycin-Resistant Gram-Positive Bacteria
P. Petersen, P. Bradford, W. Weiss, Timothy Murphy, P. Sum, S. Projan (2002)
In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 46
Jennifer Twilla, M. Gelfand, K. Cleveland, Justin Usery (2011)
Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.The Journal of antimicrobial chemotherapy, 66 11
I. Critchley, Deborah Draghi, D. Sahm, C. Thornsberry, Mark Jones, J. Karlowsky (2003)
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.The Journal of antimicrobial chemotherapy, 51 3
K. Alrabiah, Sulaiman Alola, E. Banyan, M. Shaalan, S. Johani (2016)
Characteristics and risk factors of hospital acquired – Methicillin-resistant Staphylococcus aureus (HA-MRSA) infection of pediatric patients in a tertiary care hospital in Riyadh, Saudi ArabiaInternational Journal of Pediatrics & Adolescent Medicine, 3
J. Shaw, J. Seroogy, K. Kaniga, D. Higgins, M. Kitt, S. Barriere (2005)
Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 49
M. Stryjewski, V. Chu, W. O'Riordan, B. Warren, L. Dunbar, D. Young, M. Vallée, V. Fowler, J. Morganroth, S. Barriere, M. Kitt, G. Corey (2006)
Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 50
A. Okazaki, M. Avison (2001)
Interscience Conference on Antimicrobial Agents and Chemotherapy
A. Barry, P. Fuchs, Steven Brown (2001)
In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical CentersAntimicrobial Agents and Chemotherapy, 45
T. Lodise, M. Gotfried, S. Barriere, G. Drusano (2008)
Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 52
Kimberly Leuthner, Chrissy Cheung, M. Rybak (2006)
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.The Journal of antimicrobial chemotherapy, 58 2
Studies of telavancin in cSSI
P. Loomba, J. Taneja, B. Mishra (2010)
Methicillin and Vancomycin Resistant S. aureus in Hospitalized PatientsJournal of Global Infectious Diseases, 2
M. Stryjewski, A. Lentnek, William 'riordan, J. Pullman, P. Tambyah, J. Miro, V. Fowler, S. Barriere, M. Kitt, Ralph Corey (2014)
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyBMC Infectious Diseases, 14
H. Kirst, D. Thompson, T. Nicas (1998)
Historical Yearly Usage of VancomycinAntimicrobial Agents and Chemotherapy, 42
D. Snydman, N. Jacobus, L. McDermott, J. Lonks, J. Boyce (2000)
Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 44
H. Boucher, G. Corey (2008)
Epidemiology of methicillin-resistant Staphylococcus aureus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46 Suppl 5
G. Eliopoulos, C. Wennersten, H. Gold, R. Moellering (1996)
In vitro activities in new oxazolidinone antimicrobial agents against enterococciAntimicrobial Agents and Chemotherapy, 40
J. Finks, E. Wells, Teri Dyke, N. Husain, Linda Plizga, R. Heddurshetti, M. Wilkins, J. Rudrik, J. Hageman, J. Patel, Corinne Miller (2009)
Vancomycin-Resistant Staphylococcus aureus, Michigan, USA, 2007Emerging Infectious Diseases, 15
G. Pankuch, P. Appelbaum (2008)
Postantibiotic Effects of Telavancin against 16 Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 53
W. Abdelhady, A. Bayer, R. Gonzales, Liang Li, Y. Xiong (2016)
Telavancin (TLV) is Active Against Experimental Aortic Valve Endocarditis Caused by 1 Daptomycin-Resistant (DAP-R) Methicillin-Resistant Staphylococcus aureus (MRSA) 2 Strains 3
C. Hill, K. Krause, Stacey Lewis, J. Blais, Bret Benton, M. Mammen, P. Humphrey, A. Kinana, J. Janc (2010)
Specificity of Induction of the vanA and vanB Operons in Vancomycin-Resistant Enterococci by TelavancinAntimicrobial Agents and Chemotherapy, 54
Frances Clouse, L. Hovde, J. Rotschafer (2007)
In Vitro Evaluation of the Activities of Telavancin, Cefazolin, and Vancomycin against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus in Peritoneal DialysateAntimicrobial Agents and Chemotherapy, 51
E. Goldstein, D. Citron, C. Merriam, Y. Warren, K. Tyrrell, H. Fernandez (2003)
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and CorynebacteriaAntimicrobial Agents and Chemotherapy, 47
G. Zurenko, B. Yagi, R. Schaadt, J. Allison, J. Kilburn, S. Glickman, D. Hutchinson, M. Barbachyn, S. Brickner (1996)
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsAntimicrobial Agents and Chemotherapy, 40
H. Boucher, L. Miller, R. Razonable (2010)
Serious infections caused by methicillin-resistant Staphylococcus aureus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51 Suppl 2
J. Miro, C. García-de-la-Mària, Y. Armero, Elisa de-Lazzari, D. Soy, A. Moreno, A. Río, M. Almela, C. Mestres, J. Gatell, M. Jimenez-De-Anta, F. Marco (2007)
Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 51
Maritza Barcia-Macay, S. Lemaire, M. Mingeot-Leclercq, P. Tulkens, F. Bambeke (2006)
Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.The Journal of antimicrobial chemotherapy, 58 6
A. Baltch, Raymond Smith, W. Ritz, L. Bopp (1998)
Comparison of Inhibitory and Bactericidal Activities and Postantibiotic Effects of LY333328 and Ampicillin Used Singly and in Combination against Vancomycin-Resistant Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 42
S. Wong, S. Barriere, M. Kitt, M. Goldberg (2008)
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.The Journal of antimicrobial chemotherapy, 62 4
Noe Reyes, R. Skinner, K. Kaniga, K. Krause, Josephine Shelton, G. Obedencio, Alexander Gough, Michael Conner, S. Hegde (2005)
Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 49
L. Saravolatz, G. Stein, L. Johnson (2009)
Telavancin: a novel lipoglycopeptide.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 49 12
(2014)
Theravance Inc., http://www.astellas.us/docs/us/VIBATIV_ PI_Final.pdf (2009
Jared Crandon, J. Kuti, D. Nicolau (2010)
Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia ModelAntimicrobial Agents and Chemotherapy, 54
L. Marcos, B. Camins (2010)
Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with TelavancinAntimicrobial Agents and Chemotherapy, 54
F. Lescure, M. Biendo, Y. Douadi, J. Schmit, Matthieu Eveillard (2006)
Changing epidemiology of methicillin-resistant Staphylococcus aureus and effects on cross-transmission in a teaching hospitalEuropean Journal of Clinical Microbiology and Infectious Diseases, 25
M. Stryjewski, W. O'Riordan, W. Lau, F. Pien, L. Dunbar, M. Vallée, V. Fowler, V. Chu, E. Spencer, S. Barriere, M. Kitt, M. Kitt, C. Cabell, G. Corey (2005)
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40 11
Hsin Huang, N. Flynn, J. King, C. Monchaud, M. Morita, Stuart Cohen (2006)
Comparisons of Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) and Hospital-Associated MSRA Infections in Sacramento, CaliforniaJournal of Clinical Microbiology, 44
F. Bambeke (2004)
Glycopeptides in clinical development: pharmacological profile and clinical perspectives.Current opinion in pharmacology, 4 5
Comparative activity of dalbavancin tested against 7 , 771 isolates from the USA and Europe
J. Karlowsky, K. Nichol, G. Zhanel (2015)
Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 Suppl 2
M. Nolan (2012)
Telavancin (Vibativ): a new glycopeptide antibioticEuropean Journal of Hospital Pharmacy: Science and Practice, 19
J. Pace, K. Krause, D. Johnston, D. Debabov, Terry Wu, L. Farrington, C. Lane, D. Higgins, B. Christensen, J. Judice, K. Kaniga (2003)
In Vitro Activity of TD-6424 against Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 47
(2010)
Dalbavancin, oritavancin, and telavancin: a comparative review
S. Hegde, Noe Reyes, R. Skinner, Stacey Difuntorum (2007)
Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.The Journal of antimicrobial chemotherapy, 61 1
G. Ray, J. Suaya, R. Baxter (2013)
Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based studyBMC Infectious Diseases, 13
J. Edelsberg, C. Taneja, M. Zervos, N. Haque, C. Moore, Katherine Reyes, J. Spalding, Jenny Jiang, G. Oster (2007)
Trends in US Hospital Admissions for Skin and Soft Tissue InfectionsEmerging Infectious Diseases, 15
Activity of dalbavancin against clinical isolates of staphylococci and streptococci from US and Europe
S. Brickner, D. Hutchinson, M. Barbachyn, P. Manninen, D. Ulanowicz, S. Garmon, K. Grega, S. Hendges, D. Toops, C. Ford, G. Zurenko (1996)
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.Journal of medicinal chemistry, 39 3
M. Leadbetter, Stacy Adams, Bettina Bazzini, P. Fatheree, Dane Karr, Kevin Krause, Bernice Lam, M. Linsell, Matthew Nodwell, John Pace, Kelly Quast, J. Shaw, E. Soriano, S. Trapp, Jenny Villena, Terry Wu, B. Christensen, J. Judice (2004)
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).The Journal of antibiotics, 57 5
B. Spellberg, Robert Guidos, D. Gilbert, J. Bradley, J. Bradley, Helen Boucher, W. Scheld, John Bartlett, J. Edwards (2008)
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46 2
(1879)
Program and abstracts of the 48th annual ICAA/ B Das, C Sarkar et al
V. Sakka, S. Tsiodras, Lamprini Galani, A. Antoniadou, M. Souli, I. Galani, M. Pantelaki, N. Siafakas, L. Zerva, H. Giamarellou (2008)
Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 14 1
L. Marcos, B. Camins, D. Ritchie, E. Casabar, D. Warren (2012)
Acute renal insufficiency during telavancin therapy in clinical practice.The Journal of antimicrobial chemotherapy, 67 3
G. Corey, M. Kollef, A. Shorr, E. Rubinstein, M. Stryjewski, A. Hopkins, S. Barriere (2014)
Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day SurvivalAntimicrobial Agents and Chemotherapy, 58
Telavancin (TD-6424), a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration (USFDA) had approved telavancin in 2009 for the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including MRSA (S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus group, or Enterococcus faecalis). Telavancin has two proposed mechanisms of action. In vitro, telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity. Telavancin has demonstrable in vitro activity against aerobic and anaerobic Gram-positive bacteria. Telavancin and vancomycin have similar spectra of activity. Gram-negative bacteria are usually non-susceptible to telavancin. Telavancin has been successfully tested in various animal models of bacteremia, endocarditis, meningitis, and pneumonia. Phase II Telavancin versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections due to Gram-Positive Bacteria (FAST 1 and FAST 2) and phase III [Assessment of Telavancin in Complicated Skin and Skin Structure Infections 1 (ATLAS 1 and ATLAS 2)] clinical trials have been conducted for evaluating telavancin’s efficacy and safety in cSSSIs. Phase III clinical trials have been carried out for evaluating telavancin’s safety and efficacy in nosocomial pneumonia [Assessment of Telavancin for Treatment of Hospital acquired Pneumonia 1 and 2 (ATTAIN 1 and ATTAIN 2)]. A phase II randomized, double-blind, clinical trial has been carried out for evaluating telavancin’s safety and efficacy in uncomplicated S. aureus bacteremia [Telavancin for Treatment of Uncomplicated S. aureus Bacteremia (ASSURE)]. Pacemaker lead–related infective endocarditis due to a vancomycin intermediate S. aureus (VISA) strain (non-daptomycin susceptible) was successfully treated with parenteral telavancin for 8 weeks. Telavancin extensively binds to serum albumin (~93%) and has a relatively small volume of distribution. Telavancin is not biotransformed by any cytochrome P450 microsomal enzymes and excreted mainly in the urine. Though well-tolerated, worrisome adverse effects, including renal dysfunction and QTc prolongation are of potential concern. Given its extensive binding to plasma proteins, long half-life, and a long post-antibiotic effect, it represents a promising addition to the therapeutic armamentarium in combating infections caused by resistant Gram-positive pathogens, namely, MRSA.
Therapeutic Advances in Infectious Disease – SAGE
Published: Mar 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.